Probabilities of relapse and relapse-free survival among CML and AL patients, divided into early (CR1/CP1) and late (> CR1/CP1) disease
| . | No. . | Relapse (2 y), % . | DFS (2 y), % . |
|---|---|---|---|
| PBSC | |||
| CML early disease | 39 | 3 | 64 |
| CML late disease | 12 | 21 | 45 |
| AL early disease | 17 | 0 | 68 |
| AL late disease | 37 | 57 | 25 |
| Bone marrow | |||
| CML early disease | 42 | 0 | 70 |
| CML late disease | 10 | 38 | 40 |
| AL early disease | 18 | 21 | 64 |
| AL late disease | 36 | 57 | 26 |
| . | No. . | Relapse (2 y), % . | DFS (2 y), % . |
|---|---|---|---|
| PBSC | |||
| CML early disease | 39 | 3 | 64 |
| CML late disease | 12 | 21 | 45 |
| AL early disease | 17 | 0 | 68 |
| AL late disease | 37 | 57 | 25 |
| Bone marrow | |||
| CML early disease | 42 | 0 | 70 |
| CML late disease | 10 | 38 | 40 |
| AL early disease | 18 | 21 | 64 |
| AL late disease | 36 | 57 | 26 |
DFS indicates disease-free survival.